Protara Therapeutics (TARA) said late Monday it priced an underwritten public offering of 13.7 million shares at $6.25 apiece and pre-funded warrants to purchase 2.3 million shares at $6.249 per warrant.
The company granted underwriters a 30-day option to purchase up to an additional 2.4 million shares. The offering is expected to close on Wednesday.
Protara expects gross proceeds of about $100 million.
The company aims to use the proceeds to fund clinical development and for working capital and other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments